monoclonal antibody

Acumen Pharma to present at BofA Securities conference May 14 ahead of late-2026 Alzheimer's drug trial results.

Oruka Therapeutics prices 9.66M shares at $72.50 in upsized offering, raising $700.4M with potential additional proceeds from underwriter overallotment option.

Oruka Therapeutics plans $500M public offering plus $75M underwriter option to fund monoclonal antibody pipeline for psoriasis and inflammatory conditions.

Dianthus Therapeutics CFO Ryan Savitz sold 8,224 shares for $739,000 on April 9, 2026, reducing direct holdings to zero while retaining substantial options.

Alethio Therapeutics unveils ATX-011, a first-in-class antibody for treating Essential Thrombocythemia, with IND submission targeted for Q1 2027 and clinical data expected H1 2028.

Dianthus CFO Ryan Savitz sold $9.5M in stock, liquidating all direct holdings while retaining options, following the company's exceptional 402% year-over-year rally.

AstraZeneca's tozorakimab shows positive Phase 3 COPD data, reducing exacerbations versus placebo. Stock rises 3.68% premarket; company forecasts $3-5B peak sales.

Sanofi's isatuximab subcutaneous formulation gains European regulatory endorsement for multiple myeloma, offering patients first cancer treatment with portable injector option.

Radiopharm Theranostics doses first patient in Phase 1 trial of RAD 402, a targeted radioimmune therapy for advanced prostate cancer, with data expected H2 2026.

Dupixent receives Japanese marketing authorization for bullous pemphigoid, becoming the first targeted treatment. Study showed 18% remission rate versus 4% for placebo.

Chemomab Therapeutics achieved FDA End-of-Phase 2 approval for nebokitug in PSC treatment, establishing streamlined regulatory pathway with promising Phase 2 data.

Acumen Pharmaceuticals to present Alzheimer's drug candidate sabirnetug at Stifel CNS Forum on March 18, 2026, as Phase 2 trials advance.

Jade Biosciences reports $127.4M full-year loss, maintains $336.2M cash runway through mid-2028 with pipeline data catalysts starting Q2 2026.

Teva and Blackstone Life Sciences announce $400 million four-year funding agreement to develop duvakitug for inflammatory bowel disease, supporting Teva's specialty pharma pivot.

Upstream Bio presented additional Phase 2 data for verekitug in chronic rhinosinusitis with nasal polyps, meeting primary endpoints with significant surgical intervention reduction.

Celldex presented Phase 2 data showing barzolvolimab retreatment achieves 62% and 60% complete response rates in cold urticaria and symptomatic dermographism patients.

Celldex's mast cell antibody barzolvolimab showed strong Phase 2 efficacy for urticaria, with 71% of patients achieving complete response. Phase 3 data expected Q4 2026.

Upstream Bio will present expanded VIBRANT trial data on verekitug for chronic rhinosinusitis with nasal polyps at AAAAI 2026, including new efficacy analyses accounting for rescue therapy use.

Merck's RSV antibody Enflonsia shows positive Phase 3 results, supporting FDA expansion plans to protect more at-risk infants from respiratory syncytial virus infection.

Teva and Sanofi report positive Phase 3 results for duvakitug IBD treatment, with over 55% of patients meeting efficacy endpoints. Stock rises 2.85%.